Novartis Consumer Health announces FDA approval and launch of Tavist® Allergy/Sinus/Headache
Tavist Allergy/Sinus/Headache is the only over-the-counter medication to combine the antihistamine clemastine fumarate with a nasal decongestant and pain reliever. It is indicated for treatment of allergies, sinus congestion and pressure, runny nose and sneezing, itchy, watery eyes, and itchy throat. The product began shipping to stores nationwide immediately upon FDA approval and will be found on store shelves within weeks.
Tavist Allergy/Sinus/Headache, as with all Tavist products, is PPA-free, utilizing pseudoephedrine hydrochloride as the active decongestant ingredient. The Tavist brand line also includes Tavist® Sinus and Tavist® Allergy. Tavist brand products have been marketed over the counter in the U.S. since 1992.
"With the launch of Tavist Allergy/Sinus/Headache, for the first time consumers can now choose a Tavist product that will provide complete relief of their allergy and sinus symptoms, as well as pain relief," said Barry Cohen, North American OTC Category Vice President for Novartis Consumer Health. "Consumers have placed a high level of trust and confidence in Tavist over-the-counter medications for nearly a decade, and we are certain this new Tavist product will provide them with the same quality of care they have come to expect."
Other news from the department research and development
